Authors: Ivan Tancevski, Egon Demetz, Philipp Eller, Kristina Duwensee, Julia Hoefer, Christiane Heim, Ursula Stanzl, Andreas Wehinger, Kristina Auer, Regina Karer, Julia Huber, Wilfried Schgoer, Miranda Van Eck, Jonathan Vanhoutte, Catherine Fievet, Frans Stellaard, Mats Rudling, Josef R. Patsch, Andreas Ritsch
DOI: 10.1371/journal.pone.0008722
Abstract Summary
Liver-selective thyromimetic T-0681 reduces atherosclerosis by 60% in mice by promoting reverse cholesterol transport and bile acid metabolism. The compound requires hepatic LDL receptors to lower plasma cholesterol and increase fecal sterol excretion. While long-term treatment shows promise against plaque development, early treatment may temporarily impair benefits. Clinical trials will determine if these findings translate to human atherosclerosis prevention.
Why Brain? ðŸ§
Liver-selective thyromimetic T-0681 reduces cholesterol and atherosclerosis in mice by enhancing reverse cholesterol transport and bile acid metabolism, suggesting potential for preventing heart disease in humans.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
